Asian shares were mostly lower on Monday after gains in technology stocks snapped Wall Street’s four-week losing streak. U.S.

Pfizer stock slipped about 0.7% to $25.19 after The Wall Street Journal reported on an inquiry looking into the suggestion ...

Pfizer (PFE) shares slipped on Wednesday after The Wall Street Journal reported that U.S. authorities are investigating ...

Pfizer's stock is poised for growth due to its strong pipeline, smart cost management, and recovery from COVID-19 revenue ...

Healthcare stocks have been out of vogue with investors since late 2022. Myriad reasons underlie the negative sentiment ...

Shares of Pfizer Inc. PFE slipped 1.33% to $25.21 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 1.12% to 5,712.20 and Dow ...

PFIZER INC (PFE) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 90% based on the firm’s underlying fundamentals and the stock’s valuation.

Shares of Pfizer Inc. (NYSE:PFE – Get Free Report) have received a consensus rating of “Moderate Buy” from the seventeen ...

Shares of Pfizer Inc. PFE slipped 2.26% to $25.55 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.16% to 5,776.65 and ...

Equities research analysts at Zacks Research reduced their Q2 2026 earnings per share (EPS) estimates for Pfizer in a report issued on Thursday, March 20th. Zacks Research analyst K. Shah now ...